Bimekizumab

To Advance Development of Lifesaving Treatment for Hemorrhagic Shock MA, UNITED STATES, November 18, 2025 / EINPresswire.com / -- NKA Bio, Inc is awarded $1.25M AFWERX SBIR Phase II Contract To Advance Development of Lifesaving Treatment for Hemorrhagic Shock NKA Bio, Inc ( www.NKABIO.com ) announces it has been selected by AFWERX for a SBIR Phase II contract in the amount of $1.25 million, focused on research and development of NKA01 as a dual use product for medics to buy time to get injured warfighters to lifesaving surgery, one of the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and so beginning July 2025, NKA Bio, Inc will continue its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America. NKA Bio is excited to have been selected for a second contract to continue the development of NKA01 to be used by medics to improve survivability of warfighters, injured in battle, by buying time for combat casualties to get to surgical care. “Our team is laser focused on bringing forward this novel solution for the body’s response to severe injury, hemorrhagic shock, a leading cause of fatalities,” said Susan Gann Hibbs, Co-Founder and CEO of NKA Bio, “The successful development of NKA01 will not only save lives on the battlefield but also have broad implications for trauma care here at home, strengthening our nation’s healthcare and defenses. Having the support of the Air Force and our country behind this effort helps accelerate our mission to deliver lifesaving treatment to the injured people who need it most.” The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of War, or the U.S. government. About NKA Bio, Inc. NKA Bio was founded to develop new medicines for critically ill patients that press pause on death and buy more time for life-saving care. The current focus is on developing NKA01, a low-volume temperature-stable monoclonal antibody used to treat hemorrhagic shock. NKA01 stabilizes seriously injured patients to buy time for lifesaving surgery. For more information, visit www.NKABIO.com . About AFRL The Air Force Research Laboratory, or AFRL, is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development and integration of affordable warfighting technologies for our air, space and cyberspace forces. With a workforce spanning across nine technology areas and 40 other operations around the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit afresearchlab.com . About AFWERX As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at four hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has awarded over 10,400 contracts worth more than $7.24 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: afwerx.com . Company Press Contact: Susan Gann Hibbs CEO & Co-Founder, NKA Bio, Inc Info@NKABIO.com Susan Gann Hibbs NKA BIO, Inc. Info@NKABIO.com Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake ( NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS"). On this announcement, MoonLake investors saw the price of their shares crater $55.75, or about 90%, on September 29, 2025. The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to investigate claims that, prior to September 28, 2025, MoonLake misled investors about SLK's trial design and efficacy data. The firm urges investors in MoonLake who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Mar. 10, 2024 – Sep. 29, 2025 Lead Plaintiff Deadline: Dec. 15, 2025 Visit: Contact the Firm Now: [email protected] 844-916-0895 MoonLake Immunotherapeutics (MLTX) Securities Class Action: The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial prospects was its ability to demonstrate efficacy in HS comparable or superior to a competitor's FDA-approved product ("BIMZELX"), which is used for the same HS indication and targets the same cytokines. One difference between SLK and BIMZELX is that SLK's Nanobody structure is significantly smaller than BIMZELX's monoclonal antibody format. Throughout the Class Period, MoonLake repeatedly touted SLK's structural advantages as translating into superior efficacy. The company has said that SLK could achieve benefits "a monoclonal antibody cannot do," that "the molecular advantages of our Nanobody translate into higher clinical responses for patients," and that Nanobodies "offer a more convenient and effective treatment." MoonLake also assured investors that "we really have a drug here that can become the gold standard and obviously that will facilitate any winning that we do with sonelokimab in HS." The complaint alleges that these, and other, MoonLake statements were false and misleading statements and that the company withheld crucial information from investors. More specifically, the lawsuit claims that the company misled investors about the distinction between Nanobodies and monoclonal antibodies, including that (1) SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F), (2) SLK's Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX, and (3) SLK's Nanobody structure purported increased tissue penetration would not translate to clinical efficacy. Investors learned the truth on September 28, 2025 after MoonLake revealed that only one of its two SLK Phase 3 trials achieved statistical significance – and even those results demonstrated substantially lower efficacy than BIMZELX. On this news, the price of MoonLake shares cratered $55.75 (-90%) on September 29, 2025. The following day, securities analysts described the results as "a near worst-case scenario" and proclaimed the outcome a "disastrous result." "We're focused on investors' losses and whether MoonLake may have intentionally misled investors about the SLK's purported advantages over BIMZELX while claiming that SLK could become a 'gold standard,'" said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in MoonLake and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the MoonLake case and our investigation, read more » Whistleblowers: Persons with non-public information regarding MoonLake should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. SOURCE Hagens Berman Sobol Shapiro LLP 21% more press release views with Request a Demo